Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy
暂无分享,去创建一个
F. Giardina | F. Baldanti | M. Colaneri | P. Sacchi | L. Arcaini | S. Rattotti | M. Gotti | G. Ferrari | A. Piralla | V. Zuccaro | S. Roda | T. C. Pieri | A. Ricciardi | R. Bruno | Jacqueline Ferrari
[1] Sarah E. Wilson,et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study , 2022, BMJ.
[2] H. Einsele,et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) , 2022, Leukemia.
[3] Z. Aziz,et al. “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” , 2022, PloS one.
[4] M. Shen,et al. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment , 2022, Viruses.
[5] E. Giné,et al. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19 , 2022, Haematologica.
[6] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.
[7] P. Ish,et al. Newer oral antivirals for COVID-19: Are they the real game changer? , 2022, Heart & Lung.
[8] J. Bhiman,et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.
[9] J. Skarbinski,et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.
[10] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[11] J. Butterton,et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.
[12] P. Rheeder,et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa , 2021, International Journal of Infectious Diseases.
[13] M. Muszkat,et al. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis , 2021, Scientific Reports.
[14] R. Balicer,et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting , 2021, Blood.
[15] A. Barać,et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) , 2021, Journal of Hematology & Oncology.
[16] B. Phillips,et al. SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients , 2021, European Journal of Cancer.
[17] F. Quadri,et al. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. , 2021, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[18] N. Okabe,et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient , 2020, Journal of Infection and Chemotherapy.
[19] C. Beigelman-Aubry,et al. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery , 2020, Frontiers in Immunology.
[20] W. Wood,et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.
[21] D. Skovronsky,et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[22] V. Jiménez‐Yuste,et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study , 2020, Journal of Hematology & Oncology.
[23] K. Bhaskaran,et al. Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.
[24] A. Imamura,et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan , 2020, International Journal of Clinical Oncology.
[25] S. Iyengar,et al. Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date , 2020, British journal of haematology.
[26] Xinghuan Wang,et al. Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection , 2020, Medicine.